Navigation Links
International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
Date:9/27/2007

SINGAPORE, Sept. 27 /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first natural compound to be studied in a large clinical trial focused on stroke recovery starting in the acute stage.

The CHIMES study is a multi-center double-blind placebo-controlled randomized trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment starting within 48 hours of a stroke. Already studied in a rehabilitation setting with initiation of treatment within 14 days of stroke incidence, NeuroAid(TM) will now be evaluated when administered in the acute stage, with periodic assessments for three months. The study will begin enrollment of 1,100 patients in early October 2007 at several hospitals in Singapore, followed by hospitals in the Philippines and in Thailand.

The study will be conducted by CHIMES Society, an international partnership of Key Opinion Leaders in stroke whose objective is to establish new stroke treatments.

Professor Marie-Germaine Bousser, Head of the Neurology Department at Lariboisiere Hospital in Paris, France and member of the Council of the American Stroke Association, commented, ''Recent drug trials in the acute treatment of stroke have unfortunately all been negative. It is thus very exciting to take a completely new approach and to scientifically test in different populations a compound that has long been used in Traditional Chinese Medicine.''

David Picard, CEO of Moleac, the Singapore/Biopolis-based global biopharmaceutical company that develops and markets NeuroAid(TM) outside of China, said: ''We are delighted at the interest NeuroAid(TM) has generated in the medical community worldwide. Over 200,000 patients in China alone are using NeuroAid(TM) every year, and patient feedback from other countries is very positive. Our next milestone is to generate clinical data in the acute phase, with studies that meet the standards of European and U.S
'/>"/>

SOURCE Moleac
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...ery-USMarketTrends&Analysis http://www.report...Market-Trends--Analysis.html ,, TheUSintranasa...euticapplicationsfromthedeliveryofconventionalloca...cdrugs.Thefutureofthetechnologyhingesontotheeffect...
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 1EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 3Statewide program to improve emergency care for children 54567 1Statewide program to improve emergency care for children 54567 2Scientists take early steps toward mapping epigenetic variability 9583 1Scientists take early steps toward mapping epigenetic variability 9583 2
...udy to Show That Extended,Thromboprophylaxis Reduc... Statistically Significant 44% , PARIS, July 8, 20...ed today the results of the EXCLAIM (EXtended CLin...study, which showed,the benefit of extended prophy... mobility by demonstrating the superiority of 5 we...
...Inc. (NASDAQ:INSM), a ,biopharmaceutical company f...r the treatment of metabolic diseases with unmet,...nt at this,week,s C.E. Unterberg, Towbin (CEUT) Em... City. , The conference, to be held at the Mand...om Tuesday, July 10th through Thursday,July 12th....
Other Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanetW...tionandResearch,titled"ADifficultBalance-PainManag...9issueofTheNewEnglandJournalofMedicine. ,, (Log...ALOGO ) ,, Inthearticle,WoodcockdiscussesFDAeff...orthosewhoneeditandmanagingtherisksposedbyvariousa...
(Date:11/25/2009)...Endorsements,Business,andPressJoinEfforttoEducate ...--Onceagain,theNationalBipolarFoundationandtheMedi..."Safe,tilStable"program,whichisnowbeingwidelyaccep...r.Today,theNationalBipolarFoundationreceivedaprocl...romtheLt.GovernorofLouisianaMitchLandrieu.TheNatio...
(Date:11/25/2009)...ery that grew out of a collaboration between UCLA ...ope to the nearly 10 million Americans who suffer ...wn as hardening of the arteries, peripheral arteri...m in which narrowed arteries reduce blood flow to ...for vascular disease, heart attack and stroke, and...
(Date:11/25/2009)... to fight rheumatoid arthritis, could help newly d...ESDAY, Nov. 25 (HealthDay News) -- A drug commonly...id arthritis now also shows some promise in helpin..., The drug, rituximab (Rituxan), helped patients...ough the disease had destroyed some of their pancr...
(Date:11/25/2009)... by neurological symptoms, study finds , ...gical side effects are among the potential problem...r who were treated with cisplatin-based chemothera... 1,409 Norwegian men treated for unilateral testic... a follow-up survey conducted from 1998 to 2002. ,...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
... by the researchers now reckons the evil effects o... protects against the development of brain tumors ...s done a couple of years ago , an unexpected findi...// The recent study undwells the fact that g...
...al engineering team has announced the development ... person,with an ability to deliver a visual acuity...ature television camera and an ultrasonic distance... processing the video and distance signals,// the ...
...ng history of sorts, doctors in Ohio, the United S...ar vein to a man to rid him of a painful ulcer due...his is the first time a bovine vein is used in man...ceeded very well. Dr. Hugh Beebe, the center's dir...
...chers at the Georgetown University Lombardi cancer...a protein that they say, is responsible for the sp...lled Pa 28 alpha, can also cause the spread of oth... To isolate the protein, Ngaiza and colleagues ...
...test in cardiology is OCT, which expands into Opti...de many cardiologists sit up and take notice and i...oped by Dr. Brett Bouma an assistant professor at ...ound and will allow cardiologists to view the stat...
...reakthrough using gene therapy mouthwash promises ...hwash wards off oral cancer by destroying suspicio...nt. The idea is to attack the pre-cancerous patche...nthusiastic, as the patches have disappeared compl...
Other Medicine News:Health News:Fight oral cancer with gene therapy mouthwash, 2
Ultimum Introducers
Irrigating Cannula Handpiece (Titanium)
Stronger Irrigation/Aspiration Cannula
... are designed for endomyocardial biopsies. The r... of a 3-pull ring handle, stainless steel cutting ...rotates to accommodate any position. ,A spring in...s are opened by moving the double rings away from ...
Medicine Products: